Follow
Susan Wyllie
Susan Wyllie
Verified email at dundee.ac.uk
Title
Cited by
Cited by
Year
Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need
MC Field, D Horn, AH Fairlamb, MAJ Ferguson, DW Gray, KD Read, ...
Nature Reviews Microbiology 15 (4), 217-231, 2017
4242017
Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani
S Wyllie, ML Cunningham, AH Fairlamb
Journal of Biological Chemistry 279 (38), 39925-39932, 2004
4172004
Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects
S Patterson, S Wyllie
Trends in parasitology 30 (6), 289-298, 2014
3712014
Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay
M De Rycker, I Hallyburton, J Thomas, L Campbell, S Wyllie, D Joshi, ...
Antimicrobial agents and chemotherapy 57 (7), 2913-2922, 2013
1682013
The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis
S Wyllie, S Patterson, L Stojanovski, FRC Simeons, S Norval, R Kime, ...
Science translational medicine 4 (119), 119re1-119re1, 2012
1682012
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis
AY Sokolova, S Wyllie, S Patterson, SL Oza, KD Read, AH Fairlamb
Antimicrobial agents and chemotherapy 54 (7), 2893-2900, 2010
1462010
Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition
S Wyllie, S Brand, M Thomas, M De Rycker, C Chung, I Pena, ...
Proceedings of the National Academy of Sciences 116 (19), 9318-9323, 2019
1422019
Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis
S Wyllie, M Thomas, S Patterson, S Crouch, M De Rycker, R Lowe, ...
Nature 560 (7717), 192-197, 2018
1312018
Increased levels of thiols protect antimony unresponsive Leishmania donovani field isolates against reactive oxygen species generated by trivalent antimony
G Mandal, S Wyllie, N Singh, S Sundar, AH Fairlamb, M Chatterjee
Parasitology 134 (12), 1679-1687, 2007
1212007
Clinical and veterinary trypanocidal benzoxaboroles target CPSF3
RJ Wall, E Rico, I Lukac, F Zuccotto, S Elg, IH Gilbert, Y Freund, ...
Proceedings of the National Academy of Sciences 115 (38), 9616-9621, 2018
1182018
Trypanothione biosynthesis in Leishmania major
SL Oza, MP Shaw, S Wyllie, AH Fairlamb
Molecular and biochemical parasitology 139 (1), 107-116, 2005
1142005
The Major Outer Membrane Protein of Chlamydia psittaci Functions as a Porin-Like Ion Channel
S Wyllie, RH Ashley, D Longbottom, AJ Herring
Infection and immunity 66 (11), 5202-5207, 1998
1131998
Roles of Trypanothione S-Transferase and Tryparedoxin Peroxidase in Resistance to Antimonials
S Wyllie, TJ Vickers, AH Fairlamb
Antimicrobial Agents and Chemotherapy 52 (4), 1359-1365, 2008
1042008
Differential toxicity of antimonial compounds and their effects on glutathione homeostasis in a human leukaemia monocyte cell line
S Wyllie, AH Fairlamb
Biochemical pharmacology 71 (3), 257-267, 2006
1022006
Anti-trypanosomatid drug discovery: progress and challenges
M De Rycker, S Wyllie, D Horn, KD Read, IH Gilbert
Nature Reviews Microbiology 21 (1), 35-50, 2023
972023
Chemical validation of trypanothione synthetase
LS Torrie, S Wyllie, D Spinks, SL Oza, S Thompson, JR Harrison, ...
Journal of Biological Chemistry 284 (52), 36137-36145, 2009
952009
Dissecting the essentiality of the bifunctional trypanothione synthetase‐amidase in Trypanosoma brucei using chemical and genetic methods
S Wyllie, SL Oza, S Patterson, D Spinks, S Thompson, AH Fairlamb
Molecular microbiology 74 (3), 529-540, 2009
942009
Activation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in Leishmania
S Wyllie, AJ Roberts, S Norval, S Patterson, BJ Foth, M Berriman, ...
PLoS pathogens 12 (11), e1005971, 2016
892016
Nitroheterocyclic drug resistance mechanisms in Trypanosoma brucei
S Wyllie, BJ Foth, A Kelner, AY Sokolova, M Berriman, AH Fairlamb
Journal of Antimicrobial Chemotherapy 71 (3), 625-634, 2016
892016
The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis
S Patterson, S Wyllie, S Norval, L Stojanovski, FRC Simeons, JL Auer, ...
Elife 5, e09744, 2016
852016
The system can't perform the operation now. Try again later.
Articles 1–20